News

HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.

Investigators report 12 weeks of treatment provided a strong foundation for further evaluation of TAK-279 across the psoriatic arthritis disease spectrum.

Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.

Click here to answer this week's NP & PA poll. Out of the meetings listed below, which one did you enjoy the most?

Incorporating vitamin D may mitigate adverse effects of corticosteroids, though more research is needed to discover the best methods for topical administration in vitiligo.

Study authors urge clinicians to screen adult patients with AD for cognitive dysfunction.

Christopher Bunick, MD, PhD, and David Light, CEO of Valisure, weigh in on the proposed formaldehyde ban.

Combined with routine treatments for vitiligo, certain CPMs proved efficacious in patients with vitiligo, with few adverse effects.

In this episode, discover and learn how to address the unique challenges faced by college students diagnosed with atopic dermatitis—especially as they navigate new lifestyles and medication management.

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

Keep up with the latest headlines in dermatology from the past week, including the development of a synthetic biomimetic melanin, the potential for a shortage of minoxidil, and more.

Test your knowledge on approved biologics in the management of moderate to severe atopic dermatitis and considerations for an 18-year-old man's case.

ICYMI, this week we had articles about World Psoriasis Day, the FDA approval of secukinumab for hidradenitis suppurativa, positive data of delgocitinib cream for chronic hand eczema, and more.

Polyphenols, found in certain foods, have antioxidant and anti-inflammatory properties may help modulate immune responses, offering potential adjunctive therapy for atopic dermatitis, psoriasis, and chronic urticaria.

The Sun Pharma survey included 1003 respondents with mild to moderate acne.

PASI scores were significantly correlated with sleep quality, duration, and disturbances.

Investigators believe different circulating inflammatory phenotypes in patients with vitiligo may influence their responses to treatment with ruxolitinib cream.

Delgocitinib is first-in-class pan-Janus kinase inhibitor.

The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Authors of the case report that little is known about the associations between psoriasis and renal function.

Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.

Click here to answer this week's skin cancer poll.

Additionally, investigators found that several patients in the review had rosacea induced or exacerbated by the use of topical corticosteroids on the face.

In this week’s Pointers With Portela, the 208SkinDoc explains the hidden risks associated with hair transplants.

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.

A comparative study revealed that color constancy algorithms reduce the variability of dermoscopy image quality, leading to positive outcomes for practitioners.

Learn more about the in-depth topics covered in the October 2023 print issue of Dermatology Times.

Secukinumab is currently the only IL-17A inhibitor approved for the condition.

From reducing age spots to nurturing the lip microbiome and supporting sensitive skin, 3 studies presented at the 2023 Integrative Dermatology Symposium highlighted the transformative potential of botanicals in skincare.